<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769613</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000615167</org_study_id>
    <secondary_id>PSCI-PSHCI-08-051</secondary_id>
    <nct_id>NCT00769613</nct_id>
  </id_info>
  <brief_title>Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections</brief_title>
  <official_title>Emergency Access to C.V. pp65 / IE-1 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistant or Therapy Refractory Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are
      infected with cytomegalovirus.

      PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients
      who have undergone donor stem cell transplant and have cytomegalovirus infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To provide access to cytomegalovirus (CMV) pp65- and IE-1-specific cytotoxic T
           lymphocytes (CTL) in patients with persistent CMV infections after allogeneic stem cell
           transplantation.

      Secondary

        -  To characterize CMV pp65- and IE-1-specific immune responses in terms of cytotoxicity
           and cytokine production pre-infusion and then periodically thereafter.

        -  To characterize the levels of CMV DNA in recipients of CMV pp65- and IE-1-specific CTL
           and observe whether the CTL infusion has any impact on level of virus.

        -  To determine the feasibility of CMV CTL culture from CMV-seronegative donors who have
           received a CMV vaccine.

      OUTLINE: This is a multicenter study.

      Patients receive allogeneic cytomegalovirus (CMV) pp65- and IE-1-specific cytotoxic T-cell
      lymphocytes infusion over 5 minutes on day 1. Patients may receive up to 2 more doses at
      least 2 weeks after previous dose.

      Blood samples are collected and analyzed by quantitative CMV PCR, chromium-release assays for
      CMV pp65- and IE-1-specific cytotoxicity, and immunophenotype for CD3, CD4, CD8, CD56, CD19,
      and CD45RA/RO. Intracellular cytofluorometry is used to assess IL-2, IL-4, IL-10, and IFN-γ
      production by CD4 and CD8 CMV-specific effector cells.

      After completion of study therapy, patients are followed periodically for up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to development of cytomegalovirus (CMV)-specific immune reconstitution</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMV DNA levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time during post-infusion follow-up at which the dominant CMV pp65- and IE-1 epitopes for the donor is recognized by the cytotoxic T-cell lymphocytes (CTL)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of CMV pp65- and IE-1 CTL culture after CMV vaccination of seronegative donors</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cytomegalovirus IE-1-specific cytotoxic T lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cytomegalovirus pp65-specific cytotoxic T lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunological diagnostic method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Recipient of an allogeneic stem cell transplantation

          -  Cytomegalovirus (CMV)-seropositive and meeting 1 of the following criteria:

               -  Patient has a history of CMV antigenemia for ≥ 2 weeks

               -  CMV DNA levels ≥ 600 copies/mcg of DNA despite antiviral therapy targeting CMV
                  (e.g., ganciclovir or foscarnet)

          -  No ongoing graft-vs-host disease

          -  Has donor available for peripheral blood mononuclear cell collection (for cytotoxic T
             lymphocytes production), meeting either of the following criteria:

               -  CMV-seropositive donor (≥ 2 years of age)

               -  CMV-seronegative related donor (≥ 18 years of age) who consents to receive the
                  CMV vaccine

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-3 OR Lansky PS 50-100% (for patients &lt; 16 years of age)

          -  Bilirubin &lt; 2.0 mg/dL

          -  AST and ALT &lt; 2.5 times normal

          -  Creatinine clearance ≥ 30 mL/min

          -  Pulse oximetry ≥ 94% on no more than 40% oxygen by face mask

          -  Not moribund

          -  No patients expected to survive ≤ 1 month after the T-cell infusion due to cardiac,
             pulmonary, renal, hepatic, or neurologic dysfunction

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Must be on ≤ 1 mg/kg/day of prednisone or its equivalent at the time of study CTL
             infusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth G. Lucas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>high risk metastatic gestational trophoblastic tumor</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>cytomegalovirus infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

